Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR7 | P34969 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323484 | 0.90 | KMT2A (0.61) | KMT2AKDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5326741 | 0.87 | KMT2A (0.60) | KMT2AKDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5359654 | 0.86 | KMT2A (0.62) | KMT2AHTR2AHTR7DRD2ADRA1D | |
| SCHEMBL5326779 | 0.85 | KMT2A (0.65) | KMT2AKDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5457649 | 0.84 | KMT2A (0.64) | KMT2AKDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5358772 | 0.83 | KMT2A (0.58) | KMT2AKDM4EBRD4ALDH1A1POLB | |
| SCHEMBL14386505 | 0.81 | KMT2A (0.49) | KMT2AKDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5266373 | 0.81 | CCR2 (0.65) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5328925 | 0.80 | CCR2 (0.55) | KMT2ACCR2 | |
| SCHEMBL14387005 | 0.79 | CCR2 (0.73) | KMT2ACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | KMT2A 2990/4885KDM4E 3992/4885BRD4 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.